{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:23:38Z","timestamp":1792113818306,"version":"4.4.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ijantimicag.2022.106587","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T02:46:01Z","timestamp":1649385961000},"page":"106587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Reducing the off-target endocrinologic adverse effects of azole antifungals\u2014can it be done?"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8451-2385","authenticated-orcid":false,"given":"Matthew I.","family":"Balcerek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam G.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0029-3806","authenticated-orcid":false,"given":"Paul","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syndia","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2022.106587_bib0001","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases\u2014estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0002","doi-asserted-by":"crossref","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0003","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0009-2797(78)90068-6","article-title":"Biochemical effects of miconazole on fungi. II. Inhibition of ergosterol biosynthesis in Candida albicans","volume":"21","author":"van den Bossche","year":"1978","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1517\/14728214.10.1.21","article-title":"Emerging azole antifungals","volume":"10","author":"Chen","year":"2005","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0005","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/myc.12661","article-title":"Changes in the distribution of colonising and infecting Candida spp. isolates, antifungal drug consumption and susceptibility in a French intensive care unit: a 10-year study","volume":"60","author":"Sasso","year":"2017","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0006","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jinf.2015.09.041","article-title":"Impact of antifungal prescription on relative distribution and susceptibility of Candida spp.\u2014trends over 10 years","volume":"72","author":"Bailly","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0007","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/j.clinthera.2012.09.003","article-title":"Trends in the utilization of, spending on, and prices for outpatient antifungal agents in US Medicaid programs: 1991\u20132009","volume":"34","author":"Desai","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0008","article-title":"ICU patients\u2019 antibiotic exposure and triazole-resistance in invasive candidiasis: parallel analysis of aggregated and individual data","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0009","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Br\u00fcggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","article-title":"Adverse effects associated with long-term administration of azole antifungal agents","volume":"79","author":"Benitez","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0011","series-title":"EBDM in action: developing competence in EB practice. ebdLibrary","author":"Forrest","year":"2016"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0012","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/cid\/ciq188","article-title":"Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy","volume":"52","author":"Wermers","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0013","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5500\/wjt.v11.i9.356","article-title":"Voriconazole-associated periostitis: pathophysiology, risk factors, clinical manifestations, diagnosis, and management","volume":"11","author":"Guarascio","year":"2021","journal-title":"World J Transplant"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0014","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/cid\/ciu513","article-title":"Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain","volume":"59","author":"Moon","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0015","doi-asserted-by":"crossref","first-page":"e10557","DOI":"10.1002\/jbm4.10557","article-title":"Voriconazole-associated periostitis: new insights into pathophysiology and management","volume":"6","author":"Bennett","year":"2021","journal-title":"JBMR Plus"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0016","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1182\/blood-2012-01-403030","article-title":"Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole","volume":"120","author":"Gerber","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0017","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/dmd.31.6.731","article-title":"The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human","volume":"31","author":"Roffey","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0018","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2214\/AJR.18.19991","article-title":"Spectrum of voriconazole-induced periostitis with review of the differential diagnosis","volume":"212","author":"Tan","year":"2019","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0019","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00204-020-02687-5","article-title":"Principles of fluoride toxicity and the cellular response: a review","volume":"94","author":"Johnston","year":"2020","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000325107","article-title":"Fluoride metabolism","volume":"22","author":"Buzalaf","year":"2011","journal-title":"Monogr Oral Sci"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0021","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1128\/AAC.00872-15","article-title":"Voriconazole enhances the osteogenic activity of human osteoblasts in vitro through a fluoride-independent mechanism","volume":"59","author":"Allen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2020.105605","article-title":"Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals","volume":"199","author":"Beck","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111168","article-title":"Antifungal therapy with azoles and the syndrome of acquired mineralocorticoid excess","volume":"524","author":"Beck","year":"2021","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0024","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1093\/jac\/dkaa366","article-title":"Management of posaconazole-induced pseudohyperaldosteronism","volume":"75","author":"Davis","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0039-128X(99)00087-2","article-title":"Mineralocorticoid action","volume":"65","author":"Rogerson","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0026","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bcp.2017.01.010","article-title":"Inhibition of 11\u03b2-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole","volume":"130","author":"Beck","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0027","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ancard.2014.05.007","article-title":"Itraconazole: a new drug-related cause of hypertension [in French]","volume":"63","author":"Denolle","year":"2014","journal-title":"Ann Cardiol Angeiol (Paris)"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0028","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/myc.12749","article-title":"Itraconazole induced hypertension and hypokalemia: mechanistic evaluation","volume":"61","author":"Hoffmann","year":"2018","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0029","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1530\/JOE-12-0310","article-title":"Fluconazole inhibits human adrenocortical steroidogenesis in vitro","volume":"215","author":"van der Pas","year":"2012","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0031","first-page":"e62","article-title":"Primary adrenal insufficiency secondary to chronic posaconazole use","volume":"6","author":"Araque","year":"2020","journal-title":"AACE Clin Case Rep"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0032","article-title":"Posaconazole-induced adrenal insufficiency in a case of chronic myelomonocytic leukemia","volume":"2018","author":"Miller","year":"2018","journal-title":"Case Rep Endocrinol"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0033","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0897190016646510","article-title":"Adrenal insufficiency with voriconazole and inhaled\/intranasal corticosteroids: case report and systematic review","volume":"30","author":"Duman","year":"2017","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0034","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10157-010-0305-0","article-title":"Voriconazole-associated salt-losing nephropathy","volume":"14","author":"Teranishi","year":"2010","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0035","first-page":"489","article-title":"Case of pulmonary aspergillosis associated with inappropriate antidiuretic hormone syndrome caused by voriconazole therapy [in Japanese]","volume":"45","author":"Isobe","year":"2007","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0036","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/13693786.2011.587210","article-title":"Voriconazole-associated severe hyponatremia","volume":"50","author":"Kim","year":"2012","journal-title":"Med Mycol"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0037","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/jac\/26.4.561","article-title":"Adverse events associated with itraconazole in 189 patients on chronic therapy","volume":"26","author":"Tucker","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0038","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1634\/theoncologist.2012-314","article-title":"Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer","volume":"18","author":"Antonarakis","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0039","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/j.clgc.2018.09.013","article-title":"Itraconazole as a noncastrating treatment for biochemically recurrent prostate cancer: a phase 2 study","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0040","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1002\/ccr3.3376","article-title":"Gynecomastia and hypertension in a patient treated with posaconazole","volume":"8","author":"Thompson","year":"2020","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0041","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.bmcl.2017.06.037","article-title":"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors","volume":"27","author":"Yates","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0042","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.bbmt.2015.10.021","article-title":"Correlation of pain and fluoride concentration in allogeneic hematopoietic stem cell transplant recipients on voriconazole","volume":"22","author":"Barajas","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0043","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12281-020-00371-w","article-title":"Applying pharmacogenomics to antifungal selection and dosing: are we there yet?","volume":"14","author":"Miller","year":"2020","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104311","article-title":"Drug-induced endocrine blood pressure elevation","volume":"154","author":"Beck","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0045","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01668-21","article-title":"Antifungal therapy with azoles induced the syndrome of acquired apparent mineralocorticoid excess: a literature and database analysis","volume":"66","author":"Ji","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0046","series-title":"Noxafil (posaconazole). Highlights of prescribing information","year":"2015"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0047","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1128\/AAC.03050-14","article-title":"Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia","volume":"58","author":"Duarte","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0048","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/00003246-200103000-00039","article-title":"Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients","volume":"29","author":"Albert","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0049","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1136\/pgmj.2006.047258","article-title":"Reversible acute adrenal insufficiency caused by fluconazole in a critically ill patient","volume":"82","author":"Santhana Krishnan","year":"2006","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ajh.1063","article-title":"Acute adrenal failure associated with fluconazole after administration of high-dose cyclophosphamide","volume":"66","author":"Shibata","year":"2001","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0051","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/pgmj.67.794.1084-a","article-title":"Fluconazole-associated acute adrenal insufficiency","volume":"67","author":"Gradon","year":"1991","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0052","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/clinem\/dgz206","article-title":"Dynamic pituitary\u2013adrenal interactions in the critically ill after cardiac surgery","volume":"105","author":"Gibbison","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0053","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1210\/jc.2006-0674","article-title":"Hypothalamic pituitary adrenal function during critical illness: limitations of current assessment methods","volume":"91","author":"Arafah","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0054","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.608886","article-title":"Fluconazole for hypercortisolism in Cushing's disease: a case report and literature review","volume":"11","author":"Zhao","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0055","first-page":"60","article-title":"Posaconazole: a new option for invasive fungal infection management","volume":"2","author":"Nosari","year":"2006","journal-title":"Haematol Rep"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0056","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mmcr.2016.10.002","article-title":"A case of rhino-orbital mucormycosis in diabetes with haematogenous cerebral spread","volume":"13","author":"Snaith","year":"2016","journal-title":"Med Mycol Case Rep"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0057","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3390\/jof7080620","article-title":"Severe posaconazole-induced glucocorticoid deficiency with concurrent pseudohyperaldosteronism: an unfortunate two-for-one special","volume":"7","author":"Villar-Prados","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0058","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/AAC.35.4.707","article-title":"High-dose itraconazole in the treatment of severe mycoses","volume":"35","author":"Sharkey","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0059","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ecl.2007.03.014","article-title":"Male hypogonadism in systemic disease","volume":"36","author":"Kalyani","year":"2007","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0060","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/cid\/ciz741","article-title":"Posaconazole serum drug levels associated with pseudohyperaldosteronism","volume":"70","author":"Nguyen","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0061","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/S0140-6736(13)61684-0","article-title":"Adrenal insufficiency","volume":"383","author":"Charmandari","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0062","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1128\/AAC.00146-13","article-title":"Successful management of voriconazole-associated hyponatremia with therapeutic drug monitoring","volume":"57","author":"Xu","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0063","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0064","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2174\/1568026620666200704140107","article-title":"1,2,4-Triazole: a privileged scaffold for the development of potent antifungal agents\u2014a brief review","volume":"20","author":"Tratrat","year":"2020","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104240","article-title":"History of the development of antifungal azoles: a review on structures, SAR, and mechanism of action","volume":"104","author":"Shafiei","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0066","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1016\/j.bmcl.2014.05.068","article-title":"Design and optimization of highly-selective fungal CYP51 inhibitors","volume":"24","author":"Hoekstra","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0067","doi-asserted-by":"crossref","first-page":"e1518","DOI":"10.1093\/cid\/ciaa1204","article-title":"Randomized phase 2 study of VT-1161 for the treatment of acute vulvovaginal candidiasis","volume":"73","author":"Brand","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0068","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ajog.2018.03.001","article-title":"A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis","volume":"218","author":"Brand","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0069","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/bjd.19224","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail","volume":"184","author":"Elewski","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0070","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1080\/14656566.2021.1935868","article-title":"How urgent is the need for new antifungals?","volume":"22","author":"Stewart","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0071","doi-asserted-by":"crossref","first-page":"ofaa016","DOI":"10.1093\/ofid\/ofaa016","article-title":"Hope on the horizon: novel fungal treatments in development","volume":"7","author":"Rauseo","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0072","doi-asserted-by":"crossref","first-page":"6728","DOI":"10.1074\/jbc.M117.778308","article-title":"Structural analyses of Candida albicans sterol 14\u03b1-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis","volume":"292","author":"Hargrove","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0073","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/AAC.46.1.160-165.2002","article-title":"Interaction of common azole antifungals with P glycoprotein","volume":"46","author":"Wang","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0074","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/03602532.2019.1632888","article-title":"Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism","volume":"51","author":"Schulz","year":"2019","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/gim.0b013e3182329870","article-title":"Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory","volume":"14","author":"Strom","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0076","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/0091270008327537","article-title":"CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole","volume":"49","author":"Weiss","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0077","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.bbadis.2009.10.017","article-title":"The role of 11\u03b2-hydroxysteroid dehydrogenase type 2 in human hypertension","volume":"1802","author":"Ferrari","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0078","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/HYPERTENSIONAHA.112.200741","article-title":"Common polymorphisms in the CYP11B1 and CYP11B2 genes: evidence for a digenic influence on hypertension","volume":"61","author":"Alvarez-Madrazo","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0079","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1523-1755.2005.67119.x","article-title":"Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides","volume":"67","author":"Williams","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0080","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.amjhyper.2005.02.020","article-title":"Analysis of the 11\u03b2-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension","volume":"18","author":"Mariniello","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0081","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/ckj\/sfx156","article-title":"Posaconazole-induced hypertension and hypokalemia due to inhibition of the 11\u03b2-hydroxylase enzyme","volume":"11","author":"Barton","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0082","doi-asserted-by":"crossref","first-page":"e02230","DOI":"10.1128\/AAC.02230-17","article-title":"The genetic polymorphism UGT1A4*3 is associated with low posaconazole plasma concentrations in hematological malignancy patients receiving the oral suspension","volume":"62","author":"Suh","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106587_bib0083","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/cen.13414","article-title":"A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome","volume":"87","author":"Valassi","year":"2017","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922000899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922000899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:43:46Z","timestamp":1760377426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857922000899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0924857922000899"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106587","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reducing the off-target endocrinologic adverse effects of azole antifungals\u2014can it be done?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106587","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106587"}}